Pharmaceuticals, as a treatment for human bladder cancer. Exploiting the anthracycline drug structural platform expanded as a collaborative effort with investigators from the University of Tennessee Health Science Center (Drs. Leonard Lothstein, Trevor Sweatman, Judith Soberman and Polly Hofmann) and the University of Mississippi College of Pharmacy (Dr. John Rimoldi). This research has been supported by the National Institutes of Health, the American Cancer Society, American Heart Association, Susan G. Komen for The Cure, The Pharmaceutical Manufacturers Association Foundation, and other private investment in the cumulative amount of over $10 million. Their research has produced an advanced therapeutics pipeline demonstrating commercial potential for five anthracycline compounds with novel mechanisms of action and therapeutic benefits over current therapies for the treatment of refractory cancers. The current Paradox Pharmaceuticals product pipeline includes the antitumor and cardioprotective compounds, benzarubicin and pivarubicin, the radiation enhancing agents, valrubicin and AD 36 and the non-cardiotoxic mixed-function antitumor compound, daunomustine. Daunomustine is their lead veterinary chemotherapeutic agent based on its pharmacological properties and advanced stage of clinical development. In addition to their advanced pipeline numerous related compounds are currently being investigated for both oncologic and non-oncologic therapeutic potential.